Sfoglia per AUTORE
MUSTO P
Collezione AO Cuneo

  

Items : 19

Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study. in The Lancet. Oncology / Lancet Oncol. 2023 Oct;24(10):1119-1133. doi: 10.1016/S1470-2045(23)00405-9. Epub 2023 Sep 14.

2023
AO Cuneo
AOU Città della Salute di Torino

Musto P; Boccadoro M; Gay F; Sonneveld P; Vangsted AJ; Benjamin R; Hájek R; Silkjaer T; Caers J; Zweegman S; Mancuso K; Razawy W; Tacchetti P; Offidani M; Grasso M; Giaccone L; van der Velden VHJ; Pour L; Lund T; Gadisseur A; Pietrantuono G; Roeloffzen WWH; Broijl A; Schjesvold F; Wu KL; van der Holt B; Minnema MC; van de Donk NWCJ;

Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi. in Hematological oncology / Hematol Oncol. 2023 Oct;41(4):655-662. doi: 10.1002/hon.3184. Epub 2023 May 28.

2023
AO Cuneo
ASL Biella

Gini G; Federico M; Luminari S; Marcheselli L; Catellani H; Skrypets T; Stefani PM; Pastore D; Pennese E; Liberati AM; Ballerini F; Vitolo U; Usai SV; Capponi M; Galimberti S; Perrone T; Re F; Mannina D; Musto P; Conconi A; Bari A; Massaia M; Ghiggi C; Pulsoni A; Musuraca G; Califano C; Merli M; Manni M; Nizzoli ME; et alii...

Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial. in EClinicalMedicine / EClinicalMedicine. 2023 Jun 9;60:102017. doi: 10.1016/j.eclinm.2023.102017. eCollection 2023 Jun.

2023
AO Cuneo
AOU Città della Salute di Torino

Fanti S; Tacchetti P; Zucchetta P; Pascarella A; Villanova T; De Cicco G; Patriarca F; Fioritoni F; Priola C; Sgherza N; Grasso M; Versari A; Bertamini L; Gamberi B; Albano D; Zambello R; Racca M; Galli M; Belotti A; D'Agostino M; Rota-Scalabrini D; Capra A; Gay F; Oliva S; Zamagni E; Mancuso K; Barbato S; Boccadoro M; Musto P; et alii...

Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. in The Lancet. Oncology / Lancet Oncol. 2023 Jan;24(1):64-76. doi: 10.1016/S1470-2045(22)00693-3. Epub 2022 Dec 14.

2023
AOU Città della Salute di Torino
AO Cuneo

Boccadoro M; Gay F; Ballanti S; Belotti A; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Grasso M; Zamagni E; Fioritoni F; Cea M; Pescosta N; Vincelli ID; Ronconi S; Pavone V; Capra A; Oddolo D; de Fabritiis P; Palmas A; Mina R; Paris L; Aquino S; Gamberi B; Rota-Scalabrini D; Musto P;

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts. in American journal of hematology / Am J Hematol. 2023 Aug;98(8):E204-E208. doi: 10.1002/ajh.26960. Epub 2023 May 24.

2023
ASL Città di Torino
ASL Torino 4
AO Cuneo
ASL Biella
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara
AOU Alessandria

Della Porta MG; Naldi I; Santini V; Turrini M; Giordano L; Finelli C; Pasini P; Tosi P; Tanasi I; Selleri C; Frigeni M; Sancetta R; Norata M; Marchetti M; Grimaldi D; Fianchi L; Galimberti S; Ferrara F; Di Veroli A; Di Bona E; Occhini U; Rivoli G; Bono R; Calvisi A; Castelli A; Nicolino B; Leuzzi L; Molteni A; Guarini A; et alii...

A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. in Blood advances / Blood Adv. 2022 Jan 11;6(1):327-338. doi: 10.1182/bloodadvances.2021005691.

2022
ASL Torino 5
ASL Biella
AO Cuneo
AOU Città della Salute di Torino
ASL Cuneo 1
AOU Novara
AOU Alessandria

Ladetto M; Pilerci S; Pinto A; Ramadan S; Marchesi F; Cavo M; Musto P; Coviello E; Romano A; Passamonti F; Corradini P; Krampera M; Tosi P; Lanza F; Candoni A; Selleri C; Conconi A; Visani G; Vallisa D; Venditti A; Gambacorti-Passerini C; Rigacci L; La Barbera EO; Corso A; Armiento D; Cilloni D; Cardinali V; Galimberti S; Bocchia M; et alii...

Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV. in Hematological oncology / Hematol Oncol. 2022 Dec;40(5):846-856. doi: 10.1002/hon.3048. Epub 2022 Aug 12.

2022
AO Cuneo
ASL Torino 5
AOU Città della Salute di Torino

Passamonti F; Arcaini L; Bruno R; Antonio Grossi P; Corradini P; Pagano L; Busca A; Giuliani N; Luppi M; Tosi P; Mohamed S; Corso A; Rigacci L; Giovanni Della Porta M; Lanza F; Venditti A; Massimo Lemoli R; Billio A; Gentile M; Falini B; Turrini M; Tafuri A; Morotti A; Chiara Tisi M; Galimberti S; Coviello E; Trentin L; Cuneo A; Bocchia M; et alii...

COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. in British journal of haematology / Br J Haematol. 2021 Nov;195(3):371-377. doi: 10.1111/bjh.17704. Epub 2021 Jul 16.

2021
ASL Torino 5
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Bertù L; Pagano L; Corradini P; Musto P; Petrucci L; Zaja F; Grossi PA; Visani G; Lanza F; Cattaneo C; Mina R; La Barbera EO; Cardinali V; Galimberti S; Luppi M; Armiento D; Candoni A; Krampera M; Fracchiolla N; Bocchia M; Marchesi F; Tafuri A; Pinto A; Arcaini L; Ladetto M; Massaia M; Busca A; Venditti A; Romano I; et alii...

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11.

2021
AO Cuneo
AOU Città della Salute di Torino

Boccadoro M; Cavo M; Corradini P; Petrucci MT; Zambello R; Gamberi B; Aquino S; Palmas A; de Fabritiis P; Giuliani N; D'Agostino M; Capra A; Patriarca F; Cea M; Spadano A; Grasso M; Ballanti S; Zamagni E; Ledda A; Offidani M; Galli M; Belotti A; Bertamini L; Rota-Scalabrini D; Musto P; Gay F;

Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience. in Frontiers in oncology / Front Oncol. 2021 Sep 6;11:740079. doi: 10.3389/fonc.2021.740079. eCollection 2021.

2021
AO Cuneo
AOU Città della Salute di Torino

Carella AM Jr; Cerchione C; Martinelli G; Tripepi G; Porto G; Pugliese M; Selleri C; Canale FA; Mazza P; Attolico I; Musto P; Marotta S; Di Renzo N; Scalone R; Busca A; Musso M; Giaccone L; Merla E; Colasante F; Prezioso L; Ferreri A; Loteta B; Cimminiello M; Leotta S; Storti G; Mordini N; Serio B; Vacca A; Paviglianiti A; et alii...

Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study. in Blood cancer journal / Blood Cancer J. 2020 May 18;10(5):58. doi: 10.1038/s41408-020-0326-1.

2020
ASL Biella
ASL Asti
AOU Città della Salute di Torino
ASL Vercelli
AO Cuneo
AOU Alessandria

Sonneveld P; Boccadoro M; Larocca A; Musto P; Romano A; Ria R; Giuliani N; Offidani M; Liberati AM; Marchetti M; Mosca-Siez ML; de Fabritiis P; Ballanti S; Monaco F; Gobbi M; Cellini C; Grasso M; Ronconi S; Pescosta N; Petrucci MT; Capra A; Zambello R; Mina R; Di Lullo G; Belotti A;

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. in Journal of hematology & oncology / J Hematol Oncol. 2019 Jan 9;12(1):4. doi: 10.1186/s13045-018-0691-4.

2019
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AO Cuneo
AOU Città della Salute di Torino
AOU Novara

Ria R; Vacca A; Dammacco F; Boccadoro M; Petrucci MT; Musto P; Montefusco V; Rizzo M; Gottardi D; Falcone AP; Grasso M; Leonardi G; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Patriarca F; Martino E; Larocca A; Offidani M; De Paoli L; Bringhen S; Palumbo A; Omedè P; Terragna C; Giuliani N; Morabito F; Saltarella I; et alii...

Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study. in Haematologica / Haematologica. 2019 Jan;104(1):e4-e8. doi: 10.3324/haematol.2017.183590. Epub 2018 Aug 3.

2019
ASL Torino 5
ASL Torino 4
AO Ordine Mauriziano
AO Cuneo
AOU Città della Salute di Torino

Levis A; Saglio G; Musto P; Bonferroni M; Finelli C; Tassara R; Ferrero D; Cametti G; Poloni A; Balleari E; Sanna A; Allione B; Danise P; Salvi F; Ceccarelli M; Castiglione A; Masiera E; Gioia D; Messa E; Santini V;

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. in Haematologica / Haematologica. 2019 Aug;104(8):1589-1596. doi: 10.3324/haematol.2018.205054. Epub 2019 Feb 28.

2019
AO Cuneo
AOU Città della Salute di Torino
ASL Città di Torino
AOU Alessandria

Baccarani M; Saglio G; Pane F; Ferrero D; Lunghi F; Specchia G; Iuliano F; Sorà F; Caocci G; Russo S; Musto P; Luciano L; Giai V; Sgherza N; Cavazzini F; Levato L; Stagno F; Annunziata M; Santoro M; Breccia M; Cedrone M; Latagliata R; Cattaneo D; Iurlo A; Bocchia M; Rapezzi D; Galimberti S; Crugnola M; Capodanno I; et alii...

Myelodysplastic syndromes with hypocellular marrow: Clinical characteristics and evaluation of outcome in HemaSphere

2018
ASL Biella
ASL Città di Torino
ASL Asti
ASL Torino 4
ASL Torino 5
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Alessandria
ASL Novara

Santini V; Gioia D; Masiera E; Poloni A; Ferrero D; Fragasso A; Finelli C; Salvi F; Gaidano G; Oliva EN; Catarini M; Cametti G; Bonferroni M; Danise P; Tassara R; Allione B; Cilloni D; Castelli A; Centurioni R; Ciravegna G; Visani G; Musto P; Balleari E; Biale L; Capelli D; Frairia C; Galimberti S; Giaccone L; Macchi S; et alii...

Myelodysplastic syndromes with hypocellular marrow: Clinical characteristics and evaluation of outcome in Blood

2018
ASL Asti
ASL Torino 5
AO Cuneo
AOU Città della Salute di Torino

Santini V; Gioia DM; Masiera E; Poloni A; Ferrero D; Fragasso A; Finelli C; Salvi F; Gaidano G; Oliva EN; Catarini M; Cametti G; Bonferroni M; Danise P; Tassara R; Allione B; Cilloni D; Castelli A; Centurioni R; Ciravegna G; Visani G; Musto P; Balleari E; Boveri E; Ponzoni M; Gianelli U; Della Porta MG;

The (68)Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma). in Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB) / Phys Med. 2016 May;32(5):651-6. doi: 10.1016/j.ejmp.2016.04.004. Epub 2016 Apr 28.

2016
AO Cuneo
AOU Città della Salute di Torino
AOU Novara

Gallamini A; Federico M; Vitolo U; Rigacci L; Martelli M; Balzarotti M; Luminari S; Cabras MG; Musto P; Storto G; Guerra L; Versari A; Brambilla M; Biggi A; Fioroni F; Bergesio F; Chauvie S;

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2014 Mar 1;32(7):634-40. doi: 10.1200/JCO.2013.52.0023. Epub 2014 Jan 21.

2014
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AO Cuneo
AOU Città della Salute di Torino

Montefusco V; Zambello R; Gottardi D; Franceschini L; Grasso M; Vincelli ID; Benevolo G; Levi A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Palumbo A; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; et alii...

Blastic plasmacytoid dendritic cell leukemia: Preliminary results of a retrospective italian multicentric study in Haematologica

2011
AO Cuneo

Pagano L; Valentini C; Di Paolantonio G; Melillo L; Gaidano G; Venditti A; Specchia G; Cattaneo C; Pica G; Spadea A; D'Arco A; Candoni A; Rodeghiero F; Abbadessa A; Piccin A; Ballerini F; Sorasio R; Nosari A; Caramatti C; Invernizzi R; Aversa F; Pacilli L; Musto P; Peli A; Quintini G; Forghieri F; Facchetti F; Pavan L; Leone G; et alii...